Axsome v. Alkem, Sandoz, Hikma & Unichem: Solriamfetol Patent Consolidation
Axsome Malta Ltd. and Axsome Therapeutics, Inc. asserted 13 Orange Book-listed patents covering Sunosi® (solriamfetol) against four generic manufacturers in the District of New Jersey. Filed April 5, 2024, Case No. 24-4608 was consolidated with seven related actions within 47 days, forming a unified ANDA litigation involving at least eight defendants.
Axsome’s Sunosi® ANDA litigation consolidated into single New Jersey action
On April 5, 2024, Axsome Malta Ltd. and Axsome Therapeutics, Inc. filed Case No. 2:24-cv-04608 in the District of New Jersey against Alkem Laboratories Ltd., Sandoz Inc., Hikma Pharmaceuticals USA Inc., and Unichem Laboratories Ltd. The suit alleged infringement of 13 Orange Book-listed patents covering Axsome’s Sunosi® (solriamfetol) oral tablets, a wakefulness-promoting agent approved for excessive daytime sleepiness. The patents span formulation, dosing regimen, and method-of-use claims across a cluster of related application filings made in 2022 and 2023.
The case was terminated on May 22, 2024, not on the merits, but through consolidation. Pursuant to a Stipulated Consolidation and Scheduling Order entered by the court on May 22, 2024, Case No. 24-4608 was merged with seven related Axsome actions — including the lead case No. 23-20354 filed September 13, 2023 — into a single Consolidated Action for all purposes, including discovery, case management, and trial. All four defendants in 24-4608 acknowledged service, and the consolidation was jointly requested by all parties following a court-directed status teleconference on April 30, 2024.
The 47-day lifespan of this docket reflects procedural efficiency rather than substantive resolution — the underlying patent claims remain fully live in the Consolidated Action. The rapid consolidation suggests the parties and court recognized significant overlap across the eight related cases, all targeting generic versions of Sunosi®. The ultimate merits — validity and infringement of the 13 asserted patents — remain unresolved from the public record of this specific docket, with substantive litigation expected to proceed under the consolidated caption.
Filing to Case Consolidated in 47 days
47 days from filing to consolidation — unusually swift procedural resolution for a 13-patent ANDA dispute
Case consolidated: what the procedural merger means for both parties
Consolidation is procedural — no merits decided
Case consolidation under Fed. R. Civ. P. 42(a) merges related actions for efficiency but does not adjudicate any substantive claim. The court found sufficient common questions of law and fact across the eight Sunosi® ANDA suits to warrant unified management. All patent infringement and validity issues remain open and will be litigated in the Consolidated Action under lead docket No. 23-20354.
Rule 42(a) consolidationAxsome gains coordinated enforcement across all generic challengers
Consolidation is broadly favorable to Axsome operationally. Rather than litigating the same 13 patents across eight separate tracks, Axsome will present its infringement case once, with consistent claim construction and coordinated discovery. This reduces cost exposure and mitigates the risk of inconsistent rulings. The 30-month stay triggered by the ANDA filings likely remains operative, providing continued market exclusivity during litigation.
Coordinated enforcementDefendants face a unified, high-stakes multi-patent trial
For Alkem, Sandoz, Hikma, Unichem, and the other consolidated defendants, a single merged proceeding concentrates litigation risk. Defendants may coordinate invalidity and non-infringement strategies, but must also align on claim construction positions that serve all parties. Any adverse ruling on validity or infringement in the Consolidated Action would presumptively bind all defendants, raising the stakes of each hearing significantly.
Elevated joint exposureSunosi® market entry timeline depends on consolidated outcome
Solriamfetol competes in the wakefulness and dopamine/norepinephrine reuptake inhibitor space. With 13 Orange Book patents and at least six generic filers consolidated into one action, the outcome of this litigation will set the commercial entry timeline for all challengers simultaneously. A single successful invalidity or non-infringement finding could open the market to multiple generics at once — making this consolidated action high-stakes for Axsome’s revenue position.
Multi-generic market entry riskFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Axsome Malta, Ltd. | Company | Pharmaceutical IP licensor and drug developer — holder of 13 Orange Book patents for Sunosi® (solriamfetol)Search in Eureka ↗ |
| Co-Plaintiff | Axsome Therapeutics, Inc. | Company | Search in Eureka ↗ |
| Defendant | Alkem Laboratories, Ltd. | Company | Generic pharmaceutical manufacturers seeking ANDA approval for solriamfetol oral tabletsSearch in Eureka ↗ |
| Co-Defendant | Sandoz, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Hikma Pharmaceuticals USA, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Unichem Laboratories, Ltd. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Alexander Lee Callo | Attorney | Counsel for Axsome Malta, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Charles Michael Lizza | Attorney | Counsel for Axsome Malta, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Sarah Ann Sullvian | Attorney | Counsel for Axsome Malta, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | William C. Baton | Attorney | Counsel for Axsome Malta, Ltd.Search in Eureka ↗ |
| Plaintiff law firm | Saul Ewing LLP | Law Firm | Representing Axsome Malta, Ltd.Search in Eureka ↗ |
| Defendant counsel | Rebekah R. Conroy | Attorney | Counsel for Alkem Laboratories, Ltd.Search in Eureka ↗ |
| Defendant law firm | Stone Conroy LLC | Law Firm | Representing Alkem Laboratories, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consolidation order confirms that all eight related Sunosi® ANDA actions share common questions of law and fact sufficient to warrant unified management. The stipulated nature of the order — jointly requested by all parties — suggests no party opposed consolidation, consistent with the efficiencies it offers both sides. Critically, the order makes no substantive finding on infringement or validity; all 13 asserted patents remain in dispute. The addition of Aurobindo Pharma Limited as a defendant on the consolidated docket further signals that the lead action will encompass the full universe of generic challengers to Sunosi®.
US11857528B1 and 12 further patents — Sunosi® (solriamfetol) oral tablet portfolio
The 13 Orange Book-listed patents asserted in this action — led by US11857528B1 and spanning application numbers filed between 2022 and 2023 — cover Axsome’s Sunosi® (solriamfetol) oral tablet product across multiple dimensions: formulation composition, dosing regimens, and methods of use. Solriamfetol is a dopamine and norepinephrine reuptake inhibitor (DNRI) approved for excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea. The clustering of 13 patents around a single approved product reflects a post-grant layering strategy designed to extend effective exclusivity beyond any single patent’s expiry.
The strategic significance of this patent portfolio lies in its breadth and timing. With applications filed in 2022–2023 for an already-approved drug, Axsome appears to have pursued continuation and related patent strategies to build a dense Orange Book listing. For generic manufacturers, this means that invalidating or designing around any single patent is insufficient — all 13 must be cleared. For competitors and investors, the outcome of the Consolidated Action will function as a binary event determining whether the solriamfetol generic market opens simultaneously across all challengers or remains blocked for the full litigation period.
Should you run an FTO against Axsome’s solriamfetol patent portfolio?
Any company developing, manufacturing, or distributing solriamfetol oral tablets — or closely related DNRI wakefulness-promoting compounds — should conduct a freedom-to-operate analysis against Axsome’s 13 Orange Book-listed patents. The portfolio spans formulation, dosing, and method-of-use claims, meaning product design-arounds may be technically constrained. Given the active consolidated litigation in D.N.J., the FTO landscape is dynamic: claim construction positions adopted in the Consolidated Action will directly affect the scope of each asserted patent.
PatSnap Eureka’s FTO Search Agent can map each of the 13 asserted patents against your specific compound, formulation, and intended use claims. Eureka identifies prior art gaps, tracks prosecution history for each application number, and flags claim scope changes. For CNS drug developers and generic manufacturers, running this analysis now — before the Consolidated Action reaches claim construction — provides the earliest possible signal of infringement risk and invalidity opportunity.
Run a freedom-to-operate analysis on US11857528B1 to assess your product’s exposure
Run FTO in Eureka →Similar Orange Book ANDA patent cases in D.N.J. — CNS and solriamfetol disputes
Related Orange Book ANDA infringement actions in the District of New Jersey targeting CNS and wakefulness-promoting drug patents, including comparable multi-defendant consolidations.
What this case signals for the solriamfetol and CNS ANDA IP landscape
Axsome’s aggressive multi-defendant ANDA strategy and rapid consolidation reveal key enforcement patterns worth monitoring in the CNS drug patent space.
Cluster filing is a deliberate Axsome enforcement pattern
Axsome filed eight related ANDA suits between September 2023 and April 2024, targeting every major generic filer for Sunosi®. This cluster-filing approach — each action citing Orange Book-listed patents — is consistent with a strategy to maximize 30-month stay coverage and force consolidated litigation on Axsome’s preferred timetable. Companies tracking CNS pharma ANDA disputes should monitor this pattern.
13 asserted patents signals a dense Orange Book listing strategy
The breadth of Axsome’s patent portfolio for a single drug product — 13 listed patents spanning formulation and method-of-use claims — reflects a layered exclusivity strategy common in post-Hatch-Waxman filings. Generic entrants must design around or invalidate all 13 to achieve freedom to operate. This significantly raises the cost and complexity of ANDA patent challenges for any competitor.
Axsome v Alkem — key questions answered
Case No. 2:24-cv-04608 was filed on April 5, 2024, by Axsome Malta Ltd. and Axsome Therapeutics, Inc. against Alkem Laboratories Ltd., Sandoz Inc., Hikma Pharmaceuticals USA Inc., and Unichem Laboratories Ltd., asserting 13 Orange Book patents for Sunosi® (solriamfetol). It was closed on May 22, 2024, when it was consolidated with seven related ANDA actions into a single Consolidated Action in D.N.J. No merits ruling was issued.
Axsome asserted 13 Orange Book-listed patents, including US11857528B1, US11839599B2, US11771667B1, US11793776B1, US11850227B2, US11779554B1, US11839598B2, US11865098B1, US11872204B1, US11771666B1, US11850226B2, US11872203B1, and US11850228B2. These patents cover formulations, dosing regimens, and methods of use for solriamfetol oral tablets marketed as Sunosi®.
Consolidation under Fed. R. Civ. P. 42(a) merged all eight related Axsome ANDA suits — covering Alkem, Aurobindo, Hetero, Hikma, Sandoz, and Unichem — into a single action for discovery, case management, and trial. No merits rulings were made. All defendants now face a unified proceeding, meaning claim construction and validity decisions will apply across the entire defendant group simultaneously.
Case No. 2:24-cv-04608 is closed, but the underlying patent dispute is active. The Consolidated Action — led by docket No. 23-20354 in the District of New Jersey — continues all infringement and validity claims against Alkem, Sandoz, Hikma, Unichem, Aurobindo, and Hetero. The 13 asserted solriamfetol patents remain in dispute as of the closure of this specific docket.
Solriamfetol is a dopamine and norepinephrine reuptake inhibitor (DNRI) approved by the FDA as Sunosi® for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea. Axsome holds 13 Orange Book-listed patents for the product. Generic manufacturers filed ANDAs seeking approval for generic versions, triggering Hatch-Waxman patent certification litigation. A successful generic challenge would allow multiple companies to launch competing products simultaneously.
PatSnap Eureka searches patents and litigation data to answer instantly.